atrasentan has been researched along with cediranib in 1 studies
Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (cediranib) | Trials (cediranib) | Recent Studies (post-2010) (cediranib) |
---|---|---|---|---|---|
358 | 41 | 108 | 279 | 102 | 204 |
Protein | Taxonomy | atrasentan (IC50) | cediranib (IC50) |
---|---|---|---|
Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.005 | |
Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.026 | |
Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.036 | |
Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.005 | |
Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.003 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0016 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
1 review(s) available for atrasentan and cediranib
Article | Year |
---|---|
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |